J&J will ad­vance pso­ri­a­sis drug li­censed from Pro­tag­o­nist af­ter fuller Phase IIb read­out

John­son & John­son’s oral IL-23 that it li­censed from Pro­tag­o­nist Ther­a­peu­tics will move in­to a Phase III tri­al, the health­care gi­ant said, af­ter ad­di­tion­al da­ta were re­leased on Tues­day.

The drug, known as JNJ-2113, would add a pill to J&J’s strong line­up of IL-23-tar­get­ing ther­a­pies. Re­sults from the Phase IIb FRON­TIER 1 tri­al showed that JNJ-2113 hit its pri­ma­ry and sec­ondary end­points, beat­ing place­bo when mea­sur­ing 75%, 90% and 100% im­prove­ments in skin le­sions at 16 weeks. Those re­sults held across dose groups, and were sta­tis­ti­cal­ly sig­nif­i­cant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER